News from Freeline


Freeline announced new data from its ongoing Phase 1/2 MARVEL-1 dose-finding clinical trial of FLT190 for the treatment of Fabry disease and provided updates on its pipeline programs. 

News from Freeline2021-12-13T18:27:08+01:00

News from Idorsia


Idorsia Ltd (SIX: IDIA) today announced that after the planned interim analysis of the open-label extension (OLE) of the Phase 3 MODIFY study with lucerastat for the treatment of adult patients with Fabry disease, the study will continue.

News from Idorsia2021-12-13T18:15:52+01:00

News from Sangamo Therapeutics


Sangamo Therapeutics Announces Preliminary Phase 1/2 Data Showing Tolerability and Sustained Elevated α-Gal A Enzyme Activity in Patients With Fabry Disease

News from Sangamo Therapeutics2021-11-04T17:15:33+01:00
Go to Top